{
  "schemaVersion": "INAV-BUNDLE-1",
  "slug": "glp-1-pharmacy-index",
  "title": "GLP-1 pharmacy index",
  "url": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/",
  "report": {
    "title": "GLP-1 pharmacy index",
    "date": "2026-07-10T00:00:00.000Z",
    "slug": "glp-1-pharmacy-index",
    "market": "US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels.",
    "buyer": "Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.",
    "problem": "Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.",
    "whyNow": "The market just shifted from a shortage problem to a fragmentation problem: brand GLP-1s came off the FDA shortage list in 2024-2025, compounding deadlines forced compounders out, and manufacturers simultaneously launched competing direct cash-pay channels (LillyDirect, NovoCare, plus Costco/Walmart and the TrumpRx portal in Feb 2026). That created a sprawl of prices and dose-level supply gaps that no single source normalizes, exactly when employers report GLP-1s are roughly 20% of pharmacy spend and need cost-steering data.",
    "evidence": [
      "FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.",
      "Cash-pay prices for the same molecules vary widely by channel: LillyDirect lists Zepbound vials around $299-$449/month, NovoCare offers Wegovy near $349/month (with a $199 intro for two lowest doses), Costco and Walmart advertised $499/month cash options, while standard list prices run roughly $1,000-$1,500/month.",
      "Telehealth company Ro launched a free, open-access GLP-1 Supply Tracker in May 2024 that combines crowdsourced reports with the FDA shortage list and alerts users when their drug/dose is found within 100 miles — proving real consumer demand for dose-level availability data.",
      "Employer data shows GLP-1s now make up roughly 20% of total prescription drug costs and about 10.5% of total annual employer pharmacy claims in 2025, with total GLP-1 spend up about 50% year over year — a clear B2B willingness-to-pay signal for availability and price-steering data."
    ],
    "mvp": "Launch a free consumer 'find-it-in-stock and cheapest cash price' web tool for the four brand GLP-1s by drug + dose + ZIP, seeded with crowdsourced stock reports plus normalized public price data from manufacturer direct sites (LillyDirect, NovoCare), Costco/Walmart cash programs, and a GoodRx-style price layer. Layer dose-level availability alerts on top, then expose the normalized availability+price dataset as a B2B API/feed for one or two design-partner telehealth or employer-benefits buyers.",
    "difficulty": "high",
    "confidence": 55,
    "monetization": "Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).",
    "risks": [
      "Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.",
      "Regulatory and liability exposure: showing or routing to GLP-1 sources touches HIPAA, state pharmacy law, drug-advertising rules, and the post-shortage crackdown on compounded GLP-1s — surfacing illegitimate or compounded sources could create legal risk.",
      "Incumbents already occupy the niche: Ro (a well-funded telehealth company) offers a free supply tracker as a funnel, and Medfinder offers a paid concierge stock-finding service, so a standalone index must out-execute on data freshness and the B2B feed.",
      "Demand is shortage-driven and could soften further as supply fully normalizes and GLP-1 pills arrive, compressing the consumer pain point and the window for the data business."
    ],
    "validationTest": "Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.",
    "validation": {
      "rubricVersion": "INAV-VALIDATION-2026-06-04",
      "overallScore": 51,
      "verdict": "Research",
      "summary": "Research is the current validation verdict: problem severity is the strongest signal, while competitive saturation is the main evidence gap to close before scaling the build.",
      "criteria": [
        {
          "id": "demand-signal",
          "label": "Demand signal",
          "weight": 0.24,
          "score": 5.9,
          "reasoning": "Demand looks thin because the report has 4 source-backed signal(s), an editorial confidence of 55/100, and a defined buyer in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels..",
          "evidence": [
            "FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.",
            "Target buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed."
          ]
        },
        {
          "id": "problem-severity",
          "label": "Problem severity",
          "weight": 0.22,
          "score": 6.3,
          "reasoning": "Problem severity is thin when the buyer pain, customer value, and dream-outcome scores are combined.",
          "evidence": [
            "Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.",
            "FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts."
          ]
        },
        {
          "id": "willingness-to-pay",
          "label": "Willingness to pay",
          "weight": 0.2,
          "score": 5,
          "reasoning": "Willingness to pay is weak; the model has a monetization hypothesis, but it must still be proven through paid pilots or explicit pricing objections.",
          "evidence": [
            "Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).",
            "Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed."
          ]
        },
        {
          "id": "competitive-saturation",
          "label": "Competitive saturation",
          "weight": 0.18,
          "score": 3.9,
          "reasoning": "Competitive room is reduced by 3 recorded alternative(s); the wedge must stay narrow and differentiated.",
          "evidence": [
            "Recorded alternative: Ro GLP-1 Supply Tracker",
            "Competitive score rewards a narrow wedge, not absence of research."
          ]
        },
        {
          "id": "feasibility",
          "label": "Feasibility",
          "weight": 0.16,
          "score": 4,
          "reasoning": "Feasibility is weak for a high build if the MVP is limited to the first measurable workflow.",
          "evidence": [
            "Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.",
            "Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service."
          ]
        }
      ],
      "nextValidationStep": "Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.",
      "generatedAt": "Fri Jul 10 2026 10:00:00 GMT+0200 (Central European Summer Time)"
    },
    "tags": [
      "healthtech",
      "glp-1",
      "pharmacy-data",
      "price-transparency",
      "b2b-data",
      "telehealth"
    ],
    "sources": [
      "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list",
      "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize",
      "https://www.cnbc.com/2024/05/29/ro-launches-glp-1-supply-tracker-to-help-patients-navigate-shortages.html",
      "https://www.cnbc.com/2025/12/01/eli-lilly-prices-zepbound-weight-loss-drug-vials.html",
      "https://www.shrm.org/topics-tools/news/benefits-compensation/glp1-drugs-employers-annual-claims-may-2025"
    ],
    "affiliate": false,
    "affiliateProducts": [],
    "reportGeneratedAt": "Fri Jul 10 2026 10:00:00 GMT+0200 (Central European Summer Time)",
    "oneLine": "GLP-1 pharmacy index should be tested as a narrow first-win workflow for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed..",
    "complaintSeeds": [],
    "scorecard": [
      {
        "label": "Opportunity",
        "score": 6,
        "rating": "Promising",
        "detail": "GLP-1 pharmacy index has an editorial confidence score of 55/100 before live buyer validation."
      },
      {
        "label": "Problem",
        "score": 5,
        "rating": "Promising",
        "detail": "Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time."
      },
      {
        "label": "Feasibility",
        "score": 4,
        "rating": "Needs proof",
        "detail": "A high build can work if the MVP stays limited to the first repeated workflow."
      },
      {
        "label": "Why now",
        "score": 9,
        "rating": "Exceptional",
        "detail": "The market just shifted from a shortage problem to a fragmentation problem: brand GLP-1s came off the FDA shortage list in 2024-2025, compounding deadlines forced compounders out, and manufacturers simultaneously launched competing direct cash-pay channels (LillyDirect, NovoCare, plus Costco/Walmart and the TrumpRx portal in Feb 2026). That created a sprawl of prices and dose-level supply gaps that no single source normalizes, exactly when employers report GLP-1s are roughly 20% of pharmacy spend and need cost-steering data."
      }
    ],
    "businessFit": {
      "revenuePotential": "$250K-$2M ARR potential if the wedge proves budget urgency and becomes a recurring workflow.",
      "executionDifficulty": "Execution is high; the main constraint is staying narrow enough for a first proof loop.",
      "goToMarket": "Start with manual concierge output, direct outreach, and community proof before paid acquisition.",
      "founderFit": "Best for an AI-assisted solo founder who can interview the buyer and ship a focused first version quickly."
    },
    "offerLadder": [
      {
        "stage": "lead-magnet",
        "label": "Lead magnet",
        "offer": "Glp-1 Pharmacy Index checklist",
        "price": "Free",
        "valueProvided": "Helps Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. audit the painful workflow before buying software.",
        "goal": "Capture qualified leads and learn the buyer's exact language."
      },
      {
        "stage": "frontend",
        "label": "Frontend offer",
        "offer": "Concierge review or paid template",
        "price": "$19-$99",
        "valueProvided": "Delivers the first useful output manually before automation is trusted.",
        "goal": "Validate urgency, workflow fit, and willingness to pay."
      },
      {
        "stage": "core",
        "label": "Core offer",
        "offer": "GLP-1 pharmacy index focused SaaS",
        "price": "$49-$499/month",
        "valueProvided": "Turns the recurring manual workflow into a repeatable product loop.",
        "goal": "Create the recurring revenue product after the narrow wedge survives tests."
      },
      {
        "stage": "continuity",
        "label": "Continuity",
        "offer": "Monitoring, benchmarks, and monthly reporting",
        "price": "$99-$1,000/year add-on",
        "valueProvided": "Keeps the buyer engaged with ongoing proof, saved time, or reduced risk.",
        "goal": "Increase retention and make the product part of a routine."
      },
      {
        "stage": "backend",
        "label": "Backend offer",
        "offer": "Done-with-you setup, agency, or team rollout",
        "price": "Custom",
        "valueProvided": "Adds implementation help, integrations, and workflow migration.",
        "goal": "Capture higher-value accounts once the productized wedge is proven."
      }
    ],
    "economics": {
      "pricingAnchor": {
        "offer": "GLP-1 pharmacy index focused SaaS",
        "priceLow": 49,
        "priceHigh": 499,
        "cadence": "/month",
        "basis": "Derived from this report's \"Core offer\" offer-ladder stage ($49-$499/month). These are price-anchored scenarios, not market-size claims."
      },
      "scenarios": [
        {
          "label": "Proof",
          "customers": 10,
          "mrrLow": 490,
          "mrrHigh": 4990,
          "note": "Ten paying customers proves willingness to pay and funds continued validation."
        },
        {
          "label": "Wedge",
          "customers": 50,
          "mrrLow": 2450,
          "mrrHigh": 24950,
          "note": "Fifty customers in one niche makes the workflow the default in that circle and feeds referrals."
        },
        {
          "label": "Vertical leader",
          "customers": 250,
          "mrrLow": 12250,
          "mrrHigh": 124750,
          "note": "A few hundred accounts in one vertical is a real business before any horizontal expansion."
        }
      ],
      "breakEven": "At $49-$499/month, 1 customers cover the stated Local-first MVP budget: $0-$10K before paid acquisition. budget within a month; fewer if they land at the top of the range.",
      "sizingHypothesis": "Size the buyer universe in one day: count two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying b2b buyers — telehealth prescribers, employer benefits teams, and pbms/brokers who license the availability and price feed. reachable through the report's channels (directories, associations, communities) until the list stops growing — the test only needs the first 100 names, not a TAM estimate.",
      "benchmark": "3 adjacent products recorded (2 strong). Position the price against what two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying b2b buyers — telehealth prescribers, employer benefits teams, and pbms/brokers who license the availability and price feed. already pays in time or tooling, and verify each named alternative's public pricing during the sprint."
    },
    "whyNowFactors": [
      {
        "label": "Demand visibility",
        "score": 5,
        "signal": "FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.",
        "detail": "Build only if the complaint repeats across interviews, posts, or existing workflow artifacts.",
        "evidenceUrl": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list"
      },
      {
        "label": "Tooling readiness",
        "score": 4,
        "signal": "AI-assisted product work and managed infrastructure reduce the first-version cost.",
        "detail": "The first release should automate one high-friction step rather than become a broad platform.",
        "evidenceUrl": "https://www.cnbc.com/2024/05/29/ro-launches-glp-1-supply-tracker-to-help-patients-navigate-shortages.html"
      },
      {
        "label": "Budget clarity",
        "score": 4,
        "signal": "Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).",
        "detail": "Ask for money during validation before building the full workflow.",
        "evidenceUrl": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list"
      },
      {
        "label": "Competitive window",
        "score": 8,
        "signal": "The wedge is specific enough to test without claiming the whole market.",
        "detail": "Position around one buyer and one measurable first-win outcome.",
        "evidenceUrl": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list"
      }
    ],
    "proofSignals": [
      {
        "category": "Pain",
        "score": 5,
        "title": "Repeated workflow friction",
        "detail": "FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.",
        "evidenceUrl": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list"
      },
      {
        "category": "Money",
        "score": 4,
        "title": "Budget hypothesis",
        "detail": "Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. is the first group to test because the monetization path is: Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).",
        "evidenceUrl": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list"
      },
      {
        "category": "Urgency",
        "score": 6,
        "title": "Switching pressure",
        "detail": "Urgency becomes real only if the current workaround costs time, risk, money, or reputation every week.",
        "evidenceUrl": "https://www.cnbc.com/2024/05/29/ro-launches-glp-1-supply-tracker-to-help-patients-navigate-shortages.html"
      },
      {
        "category": "Distribution",
        "score": 10,
        "title": "Reachable buyer language",
        "detail": "The first channel should be whichever source lane already contains the buyer's vocabulary.",
        "evidenceUrl": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list"
      }
    ],
    "existingProducts": [
      {
        "title": "Ro GLP-1 Supply Tracker",
        "url": "https://ro.co/weight-loss/supply-tracker/",
        "sourceName": "Ro.co",
        "sourceType": "competitor product",
        "strength": "strong",
        "rationale": "A free, open-access tool from a well-funded telehealth company that does almost exactly the consumer side of this idea — crowdsourced plus FDA-sourced dose-level GLP-1 availability with location alerts — used as a top-of-funnel acquisition channel, so it is a direct incumbent."
      },
      {
        "title": "Medfinder",
        "url": "https://www.medfinder.com/",
        "sourceName": "Medfinder",
        "sourceType": "competitor product",
        "strength": "strong",
        "rationale": "A paid concierge medication-finding service that locates GLP-1 and other hard-to-find drugs in stock near a patient, including insurance matching, competing directly on the 'find it in stock' value proposition with a revenue model already in place."
      },
      {
        "title": "GoodRx GLP-1 cost and savings guide",
        "url": "https://www.goodrx.com/classes/glp-1-agonists/glp-1-drugs-cost-and-savings",
        "sourceName": "GoodRx",
        "sourceType": "competitor product",
        "strength": "possible",
        "rationale": "GoodRx already aggregates and compares pharmacy-level GLP-1 cash prices and savings, overlapping with the price-index side of this idea and positioning it as a potential entrant or partner on price transparency, though it does not yet provide real-time dose-level stock availability."
      }
    ],
    "marketGap": {
      "underservedSegments": [
        "Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. who still run the workflow in spreadsheets, generic docs, email, or chat threads.",
        "Small teams in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels. that feel the pain weekly but are too narrow for broad incumbents.",
        "New adopters who need guided proof before committing to a larger platform."
      ],
      "featureGaps": [
        "A narrow workflow that reaches value without configuration-heavy onboarding.",
        "A buyer-facing proof artifact that shows time saved, risk reduced, or communication improved.",
        "A handoff path from manual concierge service to repeatable software."
      ],
      "differentiationLevers": [
        "Use specificity as the wedge: one buyer, one workflow, one measurable result.",
        "Show proof earlier than broad competitors with before-and-after examples and small pilot data.",
        "Keep implementation lighter than incumbent suites or generic AI assistants."
      ]
    },
    "executionPlan": {
      "businessType": "Two-sided marketplace",
      "timeline": "8-12 weeks",
      "budget": "Local-first MVP budget: $0-$10K before paid acquisition.",
      "buyerPersonas": [
        "Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.",
        "Budget owner who feels the operational cost of the broken workflow.",
        "Hands-on operator willing to pilot a narrow tool before a full rollout."
      ],
      "painPoints": [
        "Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.",
        "Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.",
        "Regulatory and liability exposure: showing or routing to GLP-1 sources touches HIPAA, state pharmacy law, drug-advertising rules, and the post-shortage crackdown on compounded GLP-1s — surfacing illegitimate or compounded sources could create legal risk."
      ],
      "mvpApproach": "Build only the first-win workflow for \"GLP-1 pharmacy index\" and keep research, setup, and exceptions manual until the wedge is proven.",
      "initialOffer": "Concierge review or paid template",
      "acquisitionChannels": [
        {
          "channel": "Community pain posts",
          "cadence": "Weekly",
          "why": "Use communities and forums where Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. already describe the painful workflow.",
          "format": "Problem teardown, interview ask, and short demo clip",
          "targetMetric": "5 qualified calls or 10 detailed replies in 7 days"
        },
        {
          "channel": "Direct outreach",
          "cadence": "Daily during validation",
          "why": "Direct conversations are the fastest way to verify budget ownership and switching cost.",
          "format": "Concierge pilot offer with a manually prepared sample",
          "targetMetric": "3 paid pilots, LOIs, or budget-owner follow-ups"
        },
        {
          "channel": "Searchable comparison content",
          "cadence": "Bi-weekly",
          "why": "Alternative and comparison pages reveal objections, pricing language, and buying intent.",
          "format": "Before-and-after page or alternatives memo for the exact workflow",
          "targetMetric": "Organic clicks, booked demos, or waitlist joins from comparison intent"
        },
        {
          "channel": "Launch directory",
          "cadence": "Once MVP is clickable",
          "why": "Launches test whether the promise is legible to people outside the first interview set.",
          "format": "Single-purpose demo and first-win story",
          "targetMetric": "25% demo completion or 10 waitlist joins"
        }
      ],
      "milestones": [
        "Interview 10 people who match the buyer persona.",
        "Ship a clickable demo or concierge workflow that produces the first useful artifact.",
        "Run one paid pilot or collect explicit pricing objections before automating the rest.",
        "Promote to a deeper build plan only after the wedge survives validation."
      ],
      "successMetrics": [
        "Problem resonance: 5+ calls or 10+ detailed replies.",
        "Activation: 25% of demo visitors complete the first-win path.",
        "Commercial pull: 3 paid pilots, LOIs, or concrete procurement next steps."
      ],
      "risks": [
        "Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.",
        "Regulatory and liability exposure: showing or routing to GLP-1 sources touches HIPAA, state pharmacy law, drug-advertising rules, and the post-shortage crackdown on compounded GLP-1s — surfacing illegitimate or compounded sources could create legal risk.",
        "Incumbents already occupy the niche: Ro (a well-funded telehealth company) offers a free supply tracker as a funnel, and Medfinder offers a paid concierge stock-finding service, so a standalone index must out-execute on data freshness and the B2B feed.",
        "Demand is shortage-driven and could soften further as supply fully normalizes and GLP-1 pills arrive, compressing the consumer pain point and the window for the data business.",
        "Trying to build a broad platform before the narrow workflow has proof."
      ],
      "nextActions": [
        "Write the one-sentence promise and test it in the strongest channel.",
        "Create the lead magnet and use it to recruit interviews.",
        "Build the smallest demo that proves the first win."
      ]
    },
    "frameworks": {
      "valueEquation": {
        "dreamOutcome": {
          "label": "Dream outcome",
          "score": 8,
          "rating": "Strong",
          "detail": "The buyer gets a visible first win around GLP-1 pharmacy index."
        },
        "perceivedLikelihood": {
          "label": "Perceived likelihood",
          "score": 6,
          "rating": "Promising",
          "detail": "Trust depends on proof, demos, and credible source links."
        },
        "timeDelay": {
          "label": "Time delay",
          "score": 4,
          "rating": "Needs proof",
          "detail": "Short setup and concierge onboarding make the promise easier to believe."
        },
        "effortAndSacrifice": {
          "label": "Effort and sacrifice",
          "score": 4,
          "rating": "Needs proof",
          "detail": "Reduce switching cost with imports, templates, and a manual migration path."
        },
        "improvements": [
          "Increase proof with a specific before-and-after demo.",
          "Reduce time to value with concierge onboarding.",
          "Remove effort by deferring integrations until one workflow is proven."
        ]
      },
      "marketMatrix": {
        "uniqueness": 8,
        "customerValue": 7,
        "quadrant": "Category king candidate",
        "detail": "High value plus high uniqueness deserves deeper research; lower uniqueness requires a clear distribution advantage."
      },
      "acp": {
        "audience": {
          "label": "Audience",
          "score": 5,
          "rating": "Promising",
          "detail": "Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed."
        },
        "community": {
          "label": "Community",
          "score": 9,
          "rating": "Exceptional",
          "detail": "Use the strongest source lane as the first reachable community."
        },
        "product": {
          "label": "Product",
          "score": 4,
          "rating": "Needs proof",
          "detail": "Keep the first product narrower than the market category."
        }
      },
      "categorization": {
        "type": "Two-sided marketplace",
        "market": "US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels.",
        "target": "Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.",
        "mainCompetitor": "Ro GLP-1 Supply Tracker",
        "trendAnalysis": "Trend and keyword signals are directional until verified with live customers and source citations."
      }
    },
    "communitySignals": [
      {
        "channel": "Reddit / forums",
        "count": "Research lane",
        "signal": "Look for complaints, workarounds, and repeated questions.",
        "firstMove": "Post a problem teardown for US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels. and ask how people solve it today."
      },
      {
        "channel": "Launch communities",
        "count": "Validation lane",
        "signal": "Launch traction shows whether the promise is legible.",
        "firstMove": "Ship a narrow demo and watch which promise gets clicks."
      },
      {
        "channel": "Review and alternative pages",
        "count": "Objection lane",
        "signal": "Pricing and alternatives expose buyer objections.",
        "firstMove": "Write an alternatives page that owns one narrow use case."
      }
    ],
    "keywordAnalysis": {
      "summary": "Keyword signals should be treated as directional. The strongest terms combine US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels., the buyer workflow, and the first output the product creates.",
      "fastestGrowing": [
        {
          "keyword": "pharmacy ai",
          "volume": "directional medium",
          "growth": "rising with AI adoption",
          "competition": "medium"
        },
        {
          "keyword": "index automation",
          "volume": "directional low",
          "growth": "steady niche demand",
          "competition": "medium"
        }
      ],
      "highestVolume": [
        {
          "keyword": "access software",
          "volume": "directional medium",
          "growth": "rising with AI adoption",
          "competition": "high"
        },
        {
          "keyword": "pricing template",
          "volume": "directional low",
          "growth": "steady niche demand",
          "competition": "medium"
        }
      ],
      "mostRelevant": [
        {
          "keyword": "pharmacy workflow",
          "volume": "directional medium",
          "growth": "rising with AI adoption",
          "competition": "medium"
        },
        {
          "keyword": "index validation",
          "volume": "directional low",
          "growth": "steady niche demand",
          "competition": "low"
        }
      ],
      "source": "IdeaNavigator AI editorial keyword heuristic",
      "freshness": "generated with the daily report"
    },
    "founderFit": {
      "score": 6,
      "idealFor": "A solo or AI-assisted founder with direct access to Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed..",
      "advantages": [
        "Can talk to the buyer before writing much code.",
        "Can ship a narrow first-win demo quickly.",
        "Can use local-first research artifacts to keep validation moving without a large team."
      ],
      "gaps": [
        "Needs real buyer access, not only desk research.",
        "Needs proof of budget or repeated urgency.",
        "Needs a crisp wedge before broad product work starts."
      ],
      "avoidIf": [
        "You cannot reach the buyer directly.",
        "The idea only sounds interesting but does not save time, money, risk, or reputation.",
        "You want to build the full platform before validating the first workflow."
      ],
      "nextMove": "Run the lead magnet and first-win demo tests before promoting the broad version."
    },
    "roast": {
      "verdict": "Promising enough to test, not strong enough to build broadly.",
      "blindSpots": [
        "Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.",
        "A broad AI assistant can flatten differentiation unless the wedge is painfully specific.",
        "The first release can become a generic dashboard if the job is not named tightly."
      ],
      "hardQuestions": [
        "Who wakes up already trying to solve this?",
        "What do they stop paying for or stop doing when this works?",
        "What proof would make a skeptical buyer trust it in one screen?",
        "What is the smallest paid version of this idea?"
      ],
      "deRiskingMoves": [
        "Sell a manual pilot before building automation.",
        "Record five exact phrases buyers use to describe the pain.",
        "Cut any feature that does not support the first measurable win."
      ]
    },
    "buildActions": [
      "Delete any report section that feels generic before building.",
      "Run the lead magnet and first-win demo tests.",
      "Promote to deeper implementation only once the wedge survives interviews or paid-pilot outreach."
    ],
    "handoffPrompts": {
      "buildPrompt": "Build a narrow MVP for \"GLP-1 pharmacy index\" for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.. Preserve the evidence, build only the first-win workflow, include source links, and treat Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed. as the first acceptance gate.",
      "reviewPrompt": "Review the \"GLP-1 pharmacy index\" MVP for over-breadth, unsupported claims, weak buyer proof, privacy risk, and missing validation instrumentation. Do not approve expansion until the kill criteria and success metrics are measurable."
    },
    "killCriteria": [
      "Fewer than five qualified buyers agree to discuss the workflow after targeted outreach.",
      "No buyer can name a current cost in time, money, risk, or reputation.",
      "The first demo does not produce a clear next step, paid pilot, or specific objection."
    ],
    "sourceDetails": [
      {
        "title": "GLP-1 No Longer on FDA's Drug Shortage List",
        "url": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list",
        "sourceType": "trade media",
        "summary": "Reports that injectable tirzepatide (Mounjaro/Zepbound) came off the FDA shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, marking the shift from a national shortage to residual, localized supply issues."
      },
      {
        "title": "Telehealth company Ro launches GLP-1 supply tracker to help patients navigate shortages",
        "url": "https://www.cnbc.com/2024/05/29/ro-launches-glp-1-supply-tracker-to-help-patients-navigate-shortages.html",
        "sourceType": "business media",
        "summary": "Describes Ro's free, open-access GLP-1 Supply Tracker that combines crowdsourced patient reports with the FDA shortage list and alerts users when a needed drug and dose is found within 100 miles, demonstrating real consumer demand for dose-level availability data."
      },
      {
        "title": "Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site",
        "url": "https://www.cnbc.com/2025/12/01/eli-lilly-prices-zepbound-weight-loss-drug-vials.html",
        "sourceType": "business media",
        "summary": "Details manufacturer cash-pay price cuts on LillyDirect for Zepbound vials and the broader self-pay GLP-1 pricing war with Novo Nordisk's NovoCare, evidencing the wide, channel-dependent price variation a price index would normalize."
      },
      {
        "title": "How Much of Employers' Annual Claims Do GLP-1 Drugs Account For?",
        "url": "https://www.shrm.org/topics-tools/news/benefits-compensation/glp1-drugs-employers-annual-claims-may-2025",
        "sourceType": "industry research",
        "summary": "SHRM analysis showing GLP-1 drugs now represent roughly 20% of total prescription drug costs and about 10.5% of total annual employer pharmacy claims in 2025, establishing the B2B buyer's cost pressure and willingness to pay for steering data."
      }
    ]
  },
  "verdict": {
    "verdict": "Research",
    "overallScore": 51,
    "summary": "Research is the current validation verdict: problem severity is the strongest signal, while competitive saturation is the main evidence gap to close before scaling the build.",
    "confidence": 55,
    "difficulty": "high"
  },
  "provenance": {
    "sourceCount": 5,
    "sources": [
      "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list",
      "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize",
      "https://www.cnbc.com/2024/05/29/ro-launches-glp-1-supply-tracker-to-help-patients-navigate-shortages.html",
      "https://www.cnbc.com/2025/12/01/eli-lilly-prices-zepbound-weight-loss-drug-vials.html",
      "https://www.shrm.org/topics-tools/news/benefits-compensation/glp1-drugs-employers-annual-claims-may-2025"
    ],
    "sourceDetails": [
      {
        "title": "GLP-1 No Longer on FDA's Drug Shortage List",
        "url": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list",
        "sourceType": "trade media",
        "summary": "Reports that injectable tirzepatide (Mounjaro/Zepbound) came off the FDA shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, marking the shift from a national shortage to residual, localized supply issues."
      },
      {
        "title": "Telehealth company Ro launches GLP-1 supply tracker to help patients navigate shortages",
        "url": "https://www.cnbc.com/2024/05/29/ro-launches-glp-1-supply-tracker-to-help-patients-navigate-shortages.html",
        "sourceType": "business media",
        "summary": "Describes Ro's free, open-access GLP-1 Supply Tracker that combines crowdsourced patient reports with the FDA shortage list and alerts users when a needed drug and dose is found within 100 miles, demonstrating real consumer demand for dose-level availability data."
      },
      {
        "title": "Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site",
        "url": "https://www.cnbc.com/2025/12/01/eli-lilly-prices-zepbound-weight-loss-drug-vials.html",
        "sourceType": "business media",
        "summary": "Details manufacturer cash-pay price cuts on LillyDirect for Zepbound vials and the broader self-pay GLP-1 pricing war with Novo Nordisk's NovoCare, evidencing the wide, channel-dependent price variation a price index would normalize."
      },
      {
        "title": "How Much of Employers' Annual Claims Do GLP-1 Drugs Account For?",
        "url": "https://www.shrm.org/topics-tools/news/benefits-compensation/glp1-drugs-employers-annual-claims-may-2025",
        "sourceType": "industry research",
        "summary": "SHRM analysis showing GLP-1 drugs now represent roughly 20% of total prescription drug costs and about 10.5% of total annual employer pharmacy claims in 2025, establishing the B2B buyer's cost pressure and willingness to pay for steering data."
      }
    ],
    "evidence": [
      "FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.",
      "Cash-pay prices for the same molecules vary widely by channel: LillyDirect lists Zepbound vials around $299-$449/month, NovoCare offers Wegovy near $349/month (with a $199 intro for two lowest doses), Costco and Walmart advertised $499/month cash options, while standard list prices run roughly $1,000-$1,500/month.",
      "Telehealth company Ro launched a free, open-access GLP-1 Supply Tracker in May 2024 that combines crowdsourced reports with the FDA shortage list and alerts users when their drug/dose is found within 100 miles — proving real consumer demand for dose-level availability data.",
      "Employer data shows GLP-1s now make up roughly 20% of total prescription drug costs and about 10.5% of total annual employer pharmacy claims in 2025, with total GLP-1 spend up about 50% year over year — a clear B2B willingness-to-pay signal for availability and price-steering data.",
      "Target buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.",
      "Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.",
      "Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).",
      "Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.",
      "Recorded alternative: Ro GLP-1 Supply Tracker",
      "Competitive score rewards a narrow wedge, not absence of research.",
      "Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service."
    ],
    "rubricVersion": "INAV-VALIDATION-2026-06-04"
  },
  "backlog": {
    "schemaVersion": "INAV-BACKLOG-1",
    "slug": "glp-1-pharmacy-index",
    "title": "GLP-1 pharmacy index",
    "generatedFrom": "frontmatter+execution-readiness",
    "vertical": {
      "name": "Retail, E-commerce & Local Services",
      "slug": "retail-consumer"
    },
    "issueCount": 6,
    "issues": [
      {
        "id": "glp-1-pharmacy-index-01-frame-the-wedge",
        "title": "[1] Frame the wedge",
        "body": "## Outcome\nWrite the one-sentence promise and test it in the strongest channel.\n## Proof to collect\nWithin 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n## Kill criterion\nFewer than five qualified buyers agree to discuss the workflow after targeted outreach.\n## Success metric\nProblem resonance: 5+ calls or 10+ detailed replies.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Write the one-sentence promise and test it in the strongest channel.\n- Build action: Delete any report section that feels generic before building.\n- Risk to watch: Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.\n## Agent build prompt\nBuild a narrow MVP for \"GLP-1 pharmacy index\" for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.. Preserve the evidence, build only the first-win workflow, include source links, and treat Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed. as the first acceptance gate.\n\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).",
        "labels": [
          "ideanavigator",
          "vertical:retail-consumer",
          "difficulty:high",
          "stage:validation",
          "verdict:research"
        ],
        "milestone": "01 Frame the wedge",
        "stage": "validation",
        "source": {
          "reportUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/",
          "backlogUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json",
          "calendarUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics"
        }
      },
      {
        "id": "glp-1-pharmacy-index-02-interview-10-people-who-match-the-buyer-persona",
        "title": "[2] Interview 10 people who match the buyer persona.",
        "body": "## Outcome\nCreate the lead magnet and use it to recruit interviews.\n## Proof to collect\nProblem resonance: 5+ calls or 10+ detailed replies.\n## Kill criterion\nNo buyer can name a current cost in time, money, risk, or reputation.\n## Success metric\nActivation: 25% of demo visitors complete the first-win path.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Create the lead magnet and use it to recruit interviews.\n- Build action: Run the lead magnet and first-win demo tests.\n- Risk to watch: Regulatory and liability exposure: showing or routing to GLP-1 sources touches HIPAA, state pharmacy law, drug-advertising rules, and the post-shortage crackdown on compounded GLP-1s — surfacing illegitimate or compounded sources could create legal risk.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).",
        "labels": [
          "ideanavigator",
          "vertical:retail-consumer",
          "difficulty:high",
          "stage:discovery",
          "verdict:research"
        ],
        "milestone": "02 Interview 10 people who match the buyer persona.",
        "stage": "discovery",
        "source": {
          "reportUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/",
          "backlogUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json",
          "calendarUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics"
        }
      },
      {
        "id": "glp-1-pharmacy-index-03-ship-a-clickable-demo-or-concierge-workflow-that-produces-the-first-useful-artifact",
        "title": "[3] Ship a clickable demo or concierge workflow that produces the first useful artifact.",
        "body": "## Outcome\nBuild the smallest demo that proves the first win.\n## Proof to collect\nActivation: 25% of demo visitors complete the first-win path.\n## Kill criterion\nThe first demo does not produce a clear next step, paid pilot, or specific objection.\n## Success metric\nCommercial pull: 3 paid pilots, LOIs, or concrete procurement next steps.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Build the smallest demo that proves the first win.\n- Build action: Promote to deeper implementation only once the wedge survives interviews or paid-pilot outreach.\n- Risk to watch: Incumbents already occupy the niche: Ro (a well-funded telehealth company) offers a free supply tracker as a funnel, and Medfinder offers a paid concierge stock-finding service, so a standalone index must out-execute on data freshness and the B2B feed.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).",
        "labels": [
          "ideanavigator",
          "vertical:retail-consumer",
          "difficulty:high",
          "stage:prototype",
          "verdict:research"
        ],
        "milestone": "03 Ship a clickable demo or concierge workflow that produces the first useful artifact.",
        "stage": "prototype",
        "source": {
          "reportUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/",
          "backlogUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json",
          "calendarUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics"
        }
      },
      {
        "id": "glp-1-pharmacy-index-04-run-one-paid-pilot-or-collect-explicit-pricing-objections-before-automating-the-rest",
        "title": "[4] Run one paid pilot or collect explicit pricing objections before automating the rest.",
        "body": "## Outcome\nDelete any report section that feels generic before building.\n## Proof to collect\nCommercial pull: 3 paid pilots, LOIs, or concrete procurement next steps.\n## Kill criterion\nFewer than five qualified buyers agree to discuss the workflow after targeted outreach.\n## Success metric\nProblem resonance: 5+ calls or 10+ detailed replies.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Write the one-sentence promise and test it in the strongest channel.\n- Build action: Delete any report section that feels generic before building.\n- Risk to watch: Demand is shortage-driven and could soften further as supply fully normalizes and GLP-1 pills arrive, compressing the consumer pain point and the window for the data business.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).",
        "labels": [
          "ideanavigator",
          "vertical:retail-consumer",
          "difficulty:high",
          "stage:pilot",
          "verdict:research"
        ],
        "milestone": "04 Run one paid pilot or collect explicit pricing objections before automating the rest.",
        "stage": "pilot",
        "source": {
          "reportUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/",
          "backlogUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json",
          "calendarUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics"
        }
      },
      {
        "id": "glp-1-pharmacy-index-05-promote-to-a-deeper-build-plan-only-after-the-wedge-survives-validation",
        "title": "[5] Promote to a deeper build plan only after the wedge survives validation.",
        "body": "## Outcome\nRun the lead magnet and first-win demo tests.\n## Proof to collect\nFewer than five qualified buyers agree to discuss the workflow after targeted outreach.\n## Kill criterion\nNo buyer can name a current cost in time, money, risk, or reputation.\n## Success metric\nActivation: 25% of demo visitors complete the first-win path.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Create the lead magnet and use it to recruit interviews.\n- Build action: Run the lead magnet and first-win demo tests.\n- Risk to watch: Trying to build a broad platform before the narrow workflow has proof.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).",
        "labels": [
          "ideanavigator",
          "vertical:retail-consumer",
          "difficulty:high",
          "stage:measurement",
          "verdict:research"
        ],
        "milestone": "05 Promote to a deeper build plan only after the wedge survives validation.",
        "stage": "measurement",
        "source": {
          "reportUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/",
          "backlogUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json",
          "calendarUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics"
        }
      },
      {
        "id": "glp-1-pharmacy-index-06-execution-checkpoint-6",
        "title": "[6] Execution checkpoint 6",
        "body": "## Outcome\nPromote to deeper implementation only once the wedge survives interviews or paid-pilot outreach.\n## Proof to collect\nPromote to a deeper build plan only after the wedge survives validation.\n## Kill criterion\nThe first demo does not produce a clear next step, paid pilot, or specific objection.\n## Success metric\nCommercial pull: 3 paid pilots, LOIs, or concrete procurement next steps.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Build the smallest demo that proves the first win.\n- Build action: Promote to deeper implementation only once the wedge survives interviews or paid-pilot outreach.\n- Risk to watch: Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).",
        "labels": [
          "ideanavigator",
          "vertical:retail-consumer",
          "difficulty:high",
          "stage:decision",
          "verdict:research"
        ],
        "milestone": "06 Execution checkpoint 6",
        "stage": "decision",
        "source": {
          "reportUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/",
          "backlogUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json",
          "calendarUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics"
        }
      }
    ],
    "exports": {
      "githubCliScript": "#!/bin/sh\nset -eu\n# IdeaNavigator backlog: GLP-1 pharmacy index\ngh issue create \\\n  --title '[1] Frame the wedge' \\\n  --body '## Outcome\nWrite the one-sentence promise and test it in the strongest channel.\n## Proof to collect\nWithin 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n## Kill criterion\nFewer than five qualified buyers agree to discuss the workflow after targeted outreach.\n## Success metric\nProblem resonance: 5+ calls or 10+ detailed replies.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Write the one-sentence promise and test it in the strongest channel.\n- Build action: Delete any report section that feels generic before building.\n- Risk to watch: Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.\n## Agent build prompt\nBuild a narrow MVP for \"GLP-1 pharmacy index\" for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.. Preserve the evidence, build only the first-win workflow, include source links, and treat Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed. as the first acceptance gate.\n\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).' \\\n  --label 'ideanavigator,vertical:retail-consumer,difficulty:high,stage:validation,verdict:research' \\\n  --milestone '01 Frame the wedge'\ngh issue create \\\n  --title '[2] Interview 10 people who match the buyer persona.' \\\n  --body '## Outcome\nCreate the lead magnet and use it to recruit interviews.\n## Proof to collect\nProblem resonance: 5+ calls or 10+ detailed replies.\n## Kill criterion\nNo buyer can name a current cost in time, money, risk, or reputation.\n## Success metric\nActivation: 25% of demo visitors complete the first-win path.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Create the lead magnet and use it to recruit interviews.\n- Build action: Run the lead magnet and first-win demo tests.\n- Risk to watch: Regulatory and liability exposure: showing or routing to GLP-1 sources touches HIPAA, state pharmacy law, drug-advertising rules, and the post-shortage crackdown on compounded GLP-1s — surfacing illegitimate or compounded sources could create legal risk.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).' \\\n  --label 'ideanavigator,vertical:retail-consumer,difficulty:high,stage:discovery,verdict:research' \\\n  --milestone '02 Interview 10 people who match the buyer persona.'\ngh issue create \\\n  --title '[3] Ship a clickable demo or concierge workflow that produces the first useful artifact.' \\\n  --body '## Outcome\nBuild the smallest demo that proves the first win.\n## Proof to collect\nActivation: 25% of demo visitors complete the first-win path.\n## Kill criterion\nThe first demo does not produce a clear next step, paid pilot, or specific objection.\n## Success metric\nCommercial pull: 3 paid pilots, LOIs, or concrete procurement next steps.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Build the smallest demo that proves the first win.\n- Build action: Promote to deeper implementation only once the wedge survives interviews or paid-pilot outreach.\n- Risk to watch: Incumbents already occupy the niche: Ro (a well-funded telehealth company) offers a free supply tracker as a funnel, and Medfinder offers a paid concierge stock-finding service, so a standalone index must out-execute on data freshness and the B2B feed.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).' \\\n  --label 'ideanavigator,vertical:retail-consumer,difficulty:high,stage:prototype,verdict:research' \\\n  --milestone '03 Ship a clickable demo or concierge workflow that produces the first useful artifact.'\ngh issue create \\\n  --title '[4] Run one paid pilot or collect explicit pricing objections before automating the rest.' \\\n  --body '## Outcome\nDelete any report section that feels generic before building.\n## Proof to collect\nCommercial pull: 3 paid pilots, LOIs, or concrete procurement next steps.\n## Kill criterion\nFewer than five qualified buyers agree to discuss the workflow after targeted outreach.\n## Success metric\nProblem resonance: 5+ calls or 10+ detailed replies.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Write the one-sentence promise and test it in the strongest channel.\n- Build action: Delete any report section that feels generic before building.\n- Risk to watch: Demand is shortage-driven and could soften further as supply fully normalizes and GLP-1 pills arrive, compressing the consumer pain point and the window for the data business.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).' \\\n  --label 'ideanavigator,vertical:retail-consumer,difficulty:high,stage:pilot,verdict:research' \\\n  --milestone '04 Run one paid pilot or collect explicit pricing objections before automating the rest.'\ngh issue create \\\n  --title '[5] Promote to a deeper build plan only after the wedge survives validation.' \\\n  --body '## Outcome\nRun the lead magnet and first-win demo tests.\n## Proof to collect\nFewer than five qualified buyers agree to discuss the workflow after targeted outreach.\n## Kill criterion\nNo buyer can name a current cost in time, money, risk, or reputation.\n## Success metric\nActivation: 25% of demo visitors complete the first-win path.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Create the lead magnet and use it to recruit interviews.\n- Build action: Run the lead magnet and first-win demo tests.\n- Risk to watch: Trying to build a broad platform before the narrow workflow has proof.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).' \\\n  --label 'ideanavigator,vertical:retail-consumer,difficulty:high,stage:measurement,verdict:research' \\\n  --milestone '05 Promote to a deeper build plan only after the wedge survives validation.'\ngh issue create \\\n  --title '[6] Execution checkpoint 6' \\\n  --body '## Outcome\nPromote to deeper implementation only once the wedge survives interviews or paid-pilot outreach.\n## Proof to collect\nPromote to a deeper build plan only after the wedge survives validation.\n## Kill criterion\nThe first demo does not produce a clear next step, paid pilot, or specific objection.\n## Success metric\nCommercial pull: 3 paid pilots, LOIs, or concrete procurement next steps.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Build the smallest demo that proves the first win.\n- Build action: Promote to deeper implementation only once the wedge survives interviews or paid-pilot outreach.\n- Risk to watch: Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).' \\\n  --label 'ideanavigator,vertical:retail-consumer,difficulty:high,stage:decision,verdict:research' \\\n  --milestone '06 Execution checkpoint 6'\n",
      "linearCliScript": "#!/bin/sh\nset -eu\n# IdeaNavigator backlog: GLP-1 pharmacy index\nlinear issue create \\\n  --title '[1] Frame the wedge' \\\n  --description '## Outcome\nWrite the one-sentence promise and test it in the strongest channel.\n## Proof to collect\nWithin 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n## Kill criterion\nFewer than five qualified buyers agree to discuss the workflow after targeted outreach.\n## Success metric\nProblem resonance: 5+ calls or 10+ detailed replies.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Write the one-sentence promise and test it in the strongest channel.\n- Build action: Delete any report section that feels generic before building.\n- Risk to watch: Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.\n## Agent build prompt\nBuild a narrow MVP for \"GLP-1 pharmacy index\" for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.. Preserve the evidence, build only the first-win workflow, include source links, and treat Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed. as the first acceptance gate.\n\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).' \\\n  --label 'ideanavigator' \\\n  --label 'vertical:retail-consumer' \\\n  --label 'difficulty:high' \\\n  --label 'stage:validation' \\\n  --label 'verdict:research'\nlinear issue create \\\n  --title '[2] Interview 10 people who match the buyer persona.' \\\n  --description '## Outcome\nCreate the lead magnet and use it to recruit interviews.\n## Proof to collect\nProblem resonance: 5+ calls or 10+ detailed replies.\n## Kill criterion\nNo buyer can name a current cost in time, money, risk, or reputation.\n## Success metric\nActivation: 25% of demo visitors complete the first-win path.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Create the lead magnet and use it to recruit interviews.\n- Build action: Run the lead magnet and first-win demo tests.\n- Risk to watch: Regulatory and liability exposure: showing or routing to GLP-1 sources touches HIPAA, state pharmacy law, drug-advertising rules, and the post-shortage crackdown on compounded GLP-1s — surfacing illegitimate or compounded sources could create legal risk.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).' \\\n  --label 'ideanavigator' \\\n  --label 'vertical:retail-consumer' \\\n  --label 'difficulty:high' \\\n  --label 'stage:discovery' \\\n  --label 'verdict:research'\nlinear issue create \\\n  --title '[3] Ship a clickable demo or concierge workflow that produces the first useful artifact.' \\\n  --description '## Outcome\nBuild the smallest demo that proves the first win.\n## Proof to collect\nActivation: 25% of demo visitors complete the first-win path.\n## Kill criterion\nThe first demo does not produce a clear next step, paid pilot, or specific objection.\n## Success metric\nCommercial pull: 3 paid pilots, LOIs, or concrete procurement next steps.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Build the smallest demo that proves the first win.\n- Build action: Promote to deeper implementation only once the wedge survives interviews or paid-pilot outreach.\n- Risk to watch: Incumbents already occupy the niche: Ro (a well-funded telehealth company) offers a free supply tracker as a funnel, and Medfinder offers a paid concierge stock-finding service, so a standalone index must out-execute on data freshness and the B2B feed.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).' \\\n  --label 'ideanavigator' \\\n  --label 'vertical:retail-consumer' \\\n  --label 'difficulty:high' \\\n  --label 'stage:prototype' \\\n  --label 'verdict:research'\nlinear issue create \\\n  --title '[4] Run one paid pilot or collect explicit pricing objections before automating the rest.' \\\n  --description '## Outcome\nDelete any report section that feels generic before building.\n## Proof to collect\nCommercial pull: 3 paid pilots, LOIs, or concrete procurement next steps.\n## Kill criterion\nFewer than five qualified buyers agree to discuss the workflow after targeted outreach.\n## Success metric\nProblem resonance: 5+ calls or 10+ detailed replies.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Write the one-sentence promise and test it in the strongest channel.\n- Build action: Delete any report section that feels generic before building.\n- Risk to watch: Demand is shortage-driven and could soften further as supply fully normalizes and GLP-1 pills arrive, compressing the consumer pain point and the window for the data business.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).' \\\n  --label 'ideanavigator' \\\n  --label 'vertical:retail-consumer' \\\n  --label 'difficulty:high' \\\n  --label 'stage:pilot' \\\n  --label 'verdict:research'\nlinear issue create \\\n  --title '[5] Promote to a deeper build plan only after the wedge survives validation.' \\\n  --description '## Outcome\nRun the lead magnet and first-win demo tests.\n## Proof to collect\nFewer than five qualified buyers agree to discuss the workflow after targeted outreach.\n## Kill criterion\nNo buyer can name a current cost in time, money, risk, or reputation.\n## Success metric\nActivation: 25% of demo visitors complete the first-win path.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Create the lead magnet and use it to recruit interviews.\n- Build action: Run the lead magnet and first-win demo tests.\n- Risk to watch: Trying to build a broad platform before the narrow workflow has proof.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).' \\\n  --label 'ideanavigator' \\\n  --label 'vertical:retail-consumer' \\\n  --label 'difficulty:high' \\\n  --label 'stage:measurement' \\\n  --label 'verdict:research'\nlinear issue create \\\n  --title '[6] Execution checkpoint 6' \\\n  --description '## Outcome\nPromote to deeper implementation only once the wedge survives interviews or paid-pilot outreach.\n## Proof to collect\nPromote to a deeper build plan only after the wedge survives validation.\n## Kill criterion\nThe first demo does not produce a clear next step, paid pilot, or specific objection.\n## Success metric\nCommercial pull: 3 paid pilots, LOIs, or concrete procurement next steps.\n## Implementation notes\n- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.\n- Validation test: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a '\\''find my dose cheapest near me'\\'' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.\n- Next action: Build the smallest demo that proves the first win.\n- Build action: Promote to deeper implementation only once the wedge survives interviews or paid-pilot outreach.\n- Risk to watch: Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.\n## Source links\n- [Full report](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/)\n- [Backlog JSON](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json)\n- [Calendar handoff](https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics)\nValidation verdict: Research (51/100).' \\\n  --label 'ideanavigator' \\\n  --label 'vertical:retail-consumer' \\\n  --label 'difficulty:high' \\\n  --label 'stage:decision' \\\n  --label 'verdict:research'\n"
    }
  },
  "decisionMemo": {
    "slug": "glp-1-pharmacy-index",
    "title": "GLP-1 pharmacy index",
    "teamVerdict": "Park",
    "rationale": "No team rationale recorded yet.",
    "reviewers": [],
    "recordedAt": "Not recorded",
    "recommendation": "Keep this parked until the team has evidence for the next validation step: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.",
    "idea": {
      "title": "GLP-1 pharmacy index",
      "date": "2026-07-10T00:00:00.000Z",
      "slug": "glp-1-pharmacy-index",
      "market": "US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels.",
      "buyer": "Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.",
      "problem": "Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.",
      "whyNow": "The market just shifted from a shortage problem to a fragmentation problem: brand GLP-1s came off the FDA shortage list in 2024-2025, compounding deadlines forced compounders out, and manufacturers simultaneously launched competing direct cash-pay channels (LillyDirect, NovoCare, plus Costco/Walmart and the TrumpRx portal in Feb 2026). That created a sprawl of prices and dose-level supply gaps that no single source normalizes, exactly when employers report GLP-1s are roughly 20% of pharmacy spend and need cost-steering data.",
      "evidence": [
        "FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.",
        "Cash-pay prices for the same molecules vary widely by channel: LillyDirect lists Zepbound vials around $299-$449/month, NovoCare offers Wegovy near $349/month (with a $199 intro for two lowest doses), Costco and Walmart advertised $499/month cash options, while standard list prices run roughly $1,000-$1,500/month.",
        "Telehealth company Ro launched a free, open-access GLP-1 Supply Tracker in May 2024 that combines crowdsourced reports with the FDA shortage list and alerts users when their drug/dose is found within 100 miles — proving real consumer demand for dose-level availability data.",
        "Employer data shows GLP-1s now make up roughly 20% of total prescription drug costs and about 10.5% of total annual employer pharmacy claims in 2025, with total GLP-1 spend up about 50% year over year — a clear B2B willingness-to-pay signal for availability and price-steering data."
      ],
      "mvp": "Launch a free consumer 'find-it-in-stock and cheapest cash price' web tool for the four brand GLP-1s by drug + dose + ZIP, seeded with crowdsourced stock reports plus normalized public price data from manufacturer direct sites (LillyDirect, NovoCare), Costco/Walmart cash programs, and a GoodRx-style price layer. Layer dose-level availability alerts on top, then expose the normalized availability+price dataset as a B2B API/feed for one or two design-partner telehealth or employer-benefits buyers.",
      "difficulty": "high",
      "confidence": 55,
      "monetization": "Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).",
      "risks": [
        "Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.",
        "Regulatory and liability exposure: showing or routing to GLP-1 sources touches HIPAA, state pharmacy law, drug-advertising rules, and the post-shortage crackdown on compounded GLP-1s — surfacing illegitimate or compounded sources could create legal risk.",
        "Incumbents already occupy the niche: Ro (a well-funded telehealth company) offers a free supply tracker as a funnel, and Medfinder offers a paid concierge stock-finding service, so a standalone index must out-execute on data freshness and the B2B feed.",
        "Demand is shortage-driven and could soften further as supply fully normalizes and GLP-1 pills arrive, compressing the consumer pain point and the window for the data business."
      ],
      "validationTest": "Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.",
      "validation": {
        "rubricVersion": "INAV-VALIDATION-2026-06-04",
        "overallScore": 51,
        "verdict": "Research",
        "summary": "Research is the current validation verdict: problem severity is the strongest signal, while competitive saturation is the main evidence gap to close before scaling the build.",
        "criteria": [
          {
            "id": "demand-signal",
            "label": "Demand signal",
            "weight": 0.24,
            "score": 5.9,
            "reasoning": "Demand looks thin because the report has 4 source-backed signal(s), an editorial confidence of 55/100, and a defined buyer in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels..",
            "evidence": [
              "FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.",
              "Target buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed."
            ]
          },
          {
            "id": "problem-severity",
            "label": "Problem severity",
            "weight": 0.22,
            "score": 6.3,
            "reasoning": "Problem severity is thin when the buyer pain, customer value, and dream-outcome scores are combined.",
            "evidence": [
              "Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.",
              "FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts."
            ]
          },
          {
            "id": "willingness-to-pay",
            "label": "Willingness to pay",
            "weight": 0.2,
            "score": 5,
            "reasoning": "Willingness to pay is weak; the model has a monetization hypothesis, but it must still be proven through paid pilots or explicit pricing objections.",
            "evidence": [
              "Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).",
              "Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed."
            ]
          },
          {
            "id": "competitive-saturation",
            "label": "Competitive saturation",
            "weight": 0.18,
            "score": 3.9,
            "reasoning": "Competitive room is reduced by 3 recorded alternative(s); the wedge must stay narrow and differentiated.",
            "evidence": [
              "Recorded alternative: Ro GLP-1 Supply Tracker",
              "Competitive score rewards a narrow wedge, not absence of research."
            ]
          },
          {
            "id": "feasibility",
            "label": "Feasibility",
            "weight": 0.16,
            "score": 4,
            "reasoning": "Feasibility is weak for a high build if the MVP is limited to the first measurable workflow.",
            "evidence": [
              "Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.",
              "Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service."
            ]
          }
        ],
        "nextValidationStep": "Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.",
        "generatedAt": "Fri Jul 10 2026 10:00:00 GMT+0200 (Central European Summer Time)"
      },
      "tags": [
        "healthtech",
        "glp-1",
        "pharmacy-data",
        "price-transparency",
        "b2b-data",
        "telehealth"
      ],
      "sources": [
        "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list",
        "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize",
        "https://www.cnbc.com/2024/05/29/ro-launches-glp-1-supply-tracker-to-help-patients-navigate-shortages.html",
        "https://www.cnbc.com/2025/12/01/eli-lilly-prices-zepbound-weight-loss-drug-vials.html",
        "https://www.shrm.org/topics-tools/news/benefits-compensation/glp1-drugs-employers-annual-claims-may-2025"
      ],
      "affiliate": false,
      "affiliateProducts": [],
      "reportGeneratedAt": "Fri Jul 10 2026 10:00:00 GMT+0200 (Central European Summer Time)",
      "oneLine": "GLP-1 pharmacy index should be tested as a narrow first-win workflow for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed..",
      "complaintSeeds": [],
      "scorecard": [
        {
          "label": "Opportunity",
          "score": 6,
          "rating": "Promising",
          "detail": "GLP-1 pharmacy index has an editorial confidence score of 55/100 before live buyer validation."
        },
        {
          "label": "Problem",
          "score": 5,
          "rating": "Promising",
          "detail": "Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time."
        },
        {
          "label": "Feasibility",
          "score": 4,
          "rating": "Needs proof",
          "detail": "A high build can work if the MVP stays limited to the first repeated workflow."
        },
        {
          "label": "Why now",
          "score": 9,
          "rating": "Exceptional",
          "detail": "The market just shifted from a shortage problem to a fragmentation problem: brand GLP-1s came off the FDA shortage list in 2024-2025, compounding deadlines forced compounders out, and manufacturers simultaneously launched competing direct cash-pay channels (LillyDirect, NovoCare, plus Costco/Walmart and the TrumpRx portal in Feb 2026). That created a sprawl of prices and dose-level supply gaps that no single source normalizes, exactly when employers report GLP-1s are roughly 20% of pharmacy spend and need cost-steering data."
        }
      ],
      "businessFit": {
        "revenuePotential": "$250K-$2M ARR potential if the wedge proves budget urgency and becomes a recurring workflow.",
        "executionDifficulty": "Execution is high; the main constraint is staying narrow enough for a first proof loop.",
        "goToMarket": "Start with manual concierge output, direct outreach, and community proof before paid acquisition.",
        "founderFit": "Best for an AI-assisted solo founder who can interview the buyer and ship a focused first version quickly."
      },
      "offerLadder": [
        {
          "stage": "lead-magnet",
          "label": "Lead magnet",
          "offer": "Glp-1 Pharmacy Index checklist",
          "price": "Free",
          "valueProvided": "Helps Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. audit the painful workflow before buying software.",
          "goal": "Capture qualified leads and learn the buyer's exact language."
        },
        {
          "stage": "frontend",
          "label": "Frontend offer",
          "offer": "Concierge review or paid template",
          "price": "$19-$99",
          "valueProvided": "Delivers the first useful output manually before automation is trusted.",
          "goal": "Validate urgency, workflow fit, and willingness to pay."
        },
        {
          "stage": "core",
          "label": "Core offer",
          "offer": "GLP-1 pharmacy index focused SaaS",
          "price": "$49-$499/month",
          "valueProvided": "Turns the recurring manual workflow into a repeatable product loop.",
          "goal": "Create the recurring revenue product after the narrow wedge survives tests."
        },
        {
          "stage": "continuity",
          "label": "Continuity",
          "offer": "Monitoring, benchmarks, and monthly reporting",
          "price": "$99-$1,000/year add-on",
          "valueProvided": "Keeps the buyer engaged with ongoing proof, saved time, or reduced risk.",
          "goal": "Increase retention and make the product part of a routine."
        },
        {
          "stage": "backend",
          "label": "Backend offer",
          "offer": "Done-with-you setup, agency, or team rollout",
          "price": "Custom",
          "valueProvided": "Adds implementation help, integrations, and workflow migration.",
          "goal": "Capture higher-value accounts once the productized wedge is proven."
        }
      ],
      "economics": {
        "pricingAnchor": {
          "offer": "GLP-1 pharmacy index focused SaaS",
          "priceLow": 49,
          "priceHigh": 499,
          "cadence": "/month",
          "basis": "Derived from this report's \"Core offer\" offer-ladder stage ($49-$499/month). These are price-anchored scenarios, not market-size claims."
        },
        "scenarios": [
          {
            "label": "Proof",
            "customers": 10,
            "mrrLow": 490,
            "mrrHigh": 4990,
            "note": "Ten paying customers proves willingness to pay and funds continued validation."
          },
          {
            "label": "Wedge",
            "customers": 50,
            "mrrLow": 2450,
            "mrrHigh": 24950,
            "note": "Fifty customers in one niche makes the workflow the default in that circle and feeds referrals."
          },
          {
            "label": "Vertical leader",
            "customers": 250,
            "mrrLow": 12250,
            "mrrHigh": 124750,
            "note": "A few hundred accounts in one vertical is a real business before any horizontal expansion."
          }
        ],
        "breakEven": "At $49-$499/month, 1 customers cover the stated Local-first MVP budget: $0-$10K before paid acquisition. budget within a month; fewer if they land at the top of the range.",
        "sizingHypothesis": "Size the buyer universe in one day: count two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying b2b buyers — telehealth prescribers, employer benefits teams, and pbms/brokers who license the availability and price feed. reachable through the report's channels (directories, associations, communities) until the list stops growing — the test only needs the first 100 names, not a TAM estimate.",
        "benchmark": "3 adjacent products recorded (2 strong). Position the price against what two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying b2b buyers — telehealth prescribers, employer benefits teams, and pbms/brokers who license the availability and price feed. already pays in time or tooling, and verify each named alternative's public pricing during the sprint."
      },
      "whyNowFactors": [
        {
          "label": "Demand visibility",
          "score": 5,
          "signal": "FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.",
          "detail": "Build only if the complaint repeats across interviews, posts, or existing workflow artifacts.",
          "evidenceUrl": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list"
        },
        {
          "label": "Tooling readiness",
          "score": 4,
          "signal": "AI-assisted product work and managed infrastructure reduce the first-version cost.",
          "detail": "The first release should automate one high-friction step rather than become a broad platform.",
          "evidenceUrl": "https://www.cnbc.com/2024/05/29/ro-launches-glp-1-supply-tracker-to-help-patients-navigate-shortages.html"
        },
        {
          "label": "Budget clarity",
          "score": 4,
          "signal": "Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).",
          "detail": "Ask for money during validation before building the full workflow.",
          "evidenceUrl": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list"
        },
        {
          "label": "Competitive window",
          "score": 8,
          "signal": "The wedge is specific enough to test without claiming the whole market.",
          "detail": "Position around one buyer and one measurable first-win outcome.",
          "evidenceUrl": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list"
        }
      ],
      "proofSignals": [
        {
          "category": "Pain",
          "score": 5,
          "title": "Repeated workflow friction",
          "detail": "FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.",
          "evidenceUrl": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list"
        },
        {
          "category": "Money",
          "score": 4,
          "title": "Budget hypothesis",
          "detail": "Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. is the first group to test because the monetization path is: Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).",
          "evidenceUrl": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list"
        },
        {
          "category": "Urgency",
          "score": 6,
          "title": "Switching pressure",
          "detail": "Urgency becomes real only if the current workaround costs time, risk, money, or reputation every week.",
          "evidenceUrl": "https://www.cnbc.com/2024/05/29/ro-launches-glp-1-supply-tracker-to-help-patients-navigate-shortages.html"
        },
        {
          "category": "Distribution",
          "score": 10,
          "title": "Reachable buyer language",
          "detail": "The first channel should be whichever source lane already contains the buyer's vocabulary.",
          "evidenceUrl": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list"
        }
      ],
      "existingProducts": [
        {
          "title": "Ro GLP-1 Supply Tracker",
          "url": "https://ro.co/weight-loss/supply-tracker/",
          "sourceName": "Ro.co",
          "sourceType": "competitor product",
          "strength": "strong",
          "rationale": "A free, open-access tool from a well-funded telehealth company that does almost exactly the consumer side of this idea — crowdsourced plus FDA-sourced dose-level GLP-1 availability with location alerts — used as a top-of-funnel acquisition channel, so it is a direct incumbent."
        },
        {
          "title": "Medfinder",
          "url": "https://www.medfinder.com/",
          "sourceName": "Medfinder",
          "sourceType": "competitor product",
          "strength": "strong",
          "rationale": "A paid concierge medication-finding service that locates GLP-1 and other hard-to-find drugs in stock near a patient, including insurance matching, competing directly on the 'find it in stock' value proposition with a revenue model already in place."
        },
        {
          "title": "GoodRx GLP-1 cost and savings guide",
          "url": "https://www.goodrx.com/classes/glp-1-agonists/glp-1-drugs-cost-and-savings",
          "sourceName": "GoodRx",
          "sourceType": "competitor product",
          "strength": "possible",
          "rationale": "GoodRx already aggregates and compares pharmacy-level GLP-1 cash prices and savings, overlapping with the price-index side of this idea and positioning it as a potential entrant or partner on price transparency, though it does not yet provide real-time dose-level stock availability."
        }
      ],
      "marketGap": {
        "underservedSegments": [
          "Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. who still run the workflow in spreadsheets, generic docs, email, or chat threads.",
          "Small teams in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels. that feel the pain weekly but are too narrow for broad incumbents.",
          "New adopters who need guided proof before committing to a larger platform."
        ],
        "featureGaps": [
          "A narrow workflow that reaches value without configuration-heavy onboarding.",
          "A buyer-facing proof artifact that shows time saved, risk reduced, or communication improved.",
          "A handoff path from manual concierge service to repeatable software."
        ],
        "differentiationLevers": [
          "Use specificity as the wedge: one buyer, one workflow, one measurable result.",
          "Show proof earlier than broad competitors with before-and-after examples and small pilot data.",
          "Keep implementation lighter than incumbent suites or generic AI assistants."
        ]
      },
      "executionPlan": {
        "businessType": "Two-sided marketplace",
        "timeline": "8-12 weeks",
        "budget": "Local-first MVP budget: $0-$10K before paid acquisition.",
        "buyerPersonas": [
          "Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.",
          "Budget owner who feels the operational cost of the broken workflow.",
          "Hands-on operator willing to pilot a narrow tool before a full rollout."
        ],
        "painPoints": [
          "Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.",
          "Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.",
          "Regulatory and liability exposure: showing or routing to GLP-1 sources touches HIPAA, state pharmacy law, drug-advertising rules, and the post-shortage crackdown on compounded GLP-1s — surfacing illegitimate or compounded sources could create legal risk."
        ],
        "mvpApproach": "Build only the first-win workflow for \"GLP-1 pharmacy index\" and keep research, setup, and exceptions manual until the wedge is proven.",
        "initialOffer": "Concierge review or paid template",
        "acquisitionChannels": [
          {
            "channel": "Community pain posts",
            "cadence": "Weekly",
            "why": "Use communities and forums where Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. already describe the painful workflow.",
            "format": "Problem teardown, interview ask, and short demo clip",
            "targetMetric": "5 qualified calls or 10 detailed replies in 7 days"
          },
          {
            "channel": "Direct outreach",
            "cadence": "Daily during validation",
            "why": "Direct conversations are the fastest way to verify budget ownership and switching cost.",
            "format": "Concierge pilot offer with a manually prepared sample",
            "targetMetric": "3 paid pilots, LOIs, or budget-owner follow-ups"
          },
          {
            "channel": "Searchable comparison content",
            "cadence": "Bi-weekly",
            "why": "Alternative and comparison pages reveal objections, pricing language, and buying intent.",
            "format": "Before-and-after page or alternatives memo for the exact workflow",
            "targetMetric": "Organic clicks, booked demos, or waitlist joins from comparison intent"
          },
          {
            "channel": "Launch directory",
            "cadence": "Once MVP is clickable",
            "why": "Launches test whether the promise is legible to people outside the first interview set.",
            "format": "Single-purpose demo and first-win story",
            "targetMetric": "25% demo completion or 10 waitlist joins"
          }
        ],
        "milestones": [
          "Interview 10 people who match the buyer persona.",
          "Ship a clickable demo or concierge workflow that produces the first useful artifact.",
          "Run one paid pilot or collect explicit pricing objections before automating the rest.",
          "Promote to a deeper build plan only after the wedge survives validation."
        ],
        "successMetrics": [
          "Problem resonance: 5+ calls or 10+ detailed replies.",
          "Activation: 25% of demo visitors complete the first-win path.",
          "Commercial pull: 3 paid pilots, LOIs, or concrete procurement next steps."
        ],
        "risks": [
          "Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.",
          "Regulatory and liability exposure: showing or routing to GLP-1 sources touches HIPAA, state pharmacy law, drug-advertising rules, and the post-shortage crackdown on compounded GLP-1s — surfacing illegitimate or compounded sources could create legal risk.",
          "Incumbents already occupy the niche: Ro (a well-funded telehealth company) offers a free supply tracker as a funnel, and Medfinder offers a paid concierge stock-finding service, so a standalone index must out-execute on data freshness and the B2B feed.",
          "Demand is shortage-driven and could soften further as supply fully normalizes and GLP-1 pills arrive, compressing the consumer pain point and the window for the data business.",
          "Trying to build a broad platform before the narrow workflow has proof."
        ],
        "nextActions": [
          "Write the one-sentence promise and test it in the strongest channel.",
          "Create the lead magnet and use it to recruit interviews.",
          "Build the smallest demo that proves the first win."
        ]
      },
      "frameworks": {
        "valueEquation": {
          "dreamOutcome": {
            "label": "Dream outcome",
            "score": 8,
            "rating": "Strong",
            "detail": "The buyer gets a visible first win around GLP-1 pharmacy index."
          },
          "perceivedLikelihood": {
            "label": "Perceived likelihood",
            "score": 6,
            "rating": "Promising",
            "detail": "Trust depends on proof, demos, and credible source links."
          },
          "timeDelay": {
            "label": "Time delay",
            "score": 4,
            "rating": "Needs proof",
            "detail": "Short setup and concierge onboarding make the promise easier to believe."
          },
          "effortAndSacrifice": {
            "label": "Effort and sacrifice",
            "score": 4,
            "rating": "Needs proof",
            "detail": "Reduce switching cost with imports, templates, and a manual migration path."
          },
          "improvements": [
            "Increase proof with a specific before-and-after demo.",
            "Reduce time to value with concierge onboarding.",
            "Remove effort by deferring integrations until one workflow is proven."
          ]
        },
        "marketMatrix": {
          "uniqueness": 8,
          "customerValue": 7,
          "quadrant": "Category king candidate",
          "detail": "High value plus high uniqueness deserves deeper research; lower uniqueness requires a clear distribution advantage."
        },
        "acp": {
          "audience": {
            "label": "Audience",
            "score": 5,
            "rating": "Promising",
            "detail": "Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed."
          },
          "community": {
            "label": "Community",
            "score": 9,
            "rating": "Exceptional",
            "detail": "Use the strongest source lane as the first reachable community."
          },
          "product": {
            "label": "Product",
            "score": 4,
            "rating": "Needs proof",
            "detail": "Keep the first product narrower than the market category."
          }
        },
        "categorization": {
          "type": "Two-sided marketplace",
          "market": "US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels.",
          "target": "Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.",
          "mainCompetitor": "Ro GLP-1 Supply Tracker",
          "trendAnalysis": "Trend and keyword signals are directional until verified with live customers and source citations."
        }
      },
      "communitySignals": [
        {
          "channel": "Reddit / forums",
          "count": "Research lane",
          "signal": "Look for complaints, workarounds, and repeated questions.",
          "firstMove": "Post a problem teardown for US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels. and ask how people solve it today."
        },
        {
          "channel": "Launch communities",
          "count": "Validation lane",
          "signal": "Launch traction shows whether the promise is legible.",
          "firstMove": "Ship a narrow demo and watch which promise gets clicks."
        },
        {
          "channel": "Review and alternative pages",
          "count": "Objection lane",
          "signal": "Pricing and alternatives expose buyer objections.",
          "firstMove": "Write an alternatives page that owns one narrow use case."
        }
      ],
      "keywordAnalysis": {
        "summary": "Keyword signals should be treated as directional. The strongest terms combine US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels., the buyer workflow, and the first output the product creates.",
        "fastestGrowing": [
          {
            "keyword": "pharmacy ai",
            "volume": "directional medium",
            "growth": "rising with AI adoption",
            "competition": "medium"
          },
          {
            "keyword": "index automation",
            "volume": "directional low",
            "growth": "steady niche demand",
            "competition": "medium"
          }
        ],
        "highestVolume": [
          {
            "keyword": "access software",
            "volume": "directional medium",
            "growth": "rising with AI adoption",
            "competition": "high"
          },
          {
            "keyword": "pricing template",
            "volume": "directional low",
            "growth": "steady niche demand",
            "competition": "medium"
          }
        ],
        "mostRelevant": [
          {
            "keyword": "pharmacy workflow",
            "volume": "directional medium",
            "growth": "rising with AI adoption",
            "competition": "medium"
          },
          {
            "keyword": "index validation",
            "volume": "directional low",
            "growth": "steady niche demand",
            "competition": "low"
          }
        ],
        "source": "IdeaNavigator AI editorial keyword heuristic",
        "freshness": "generated with the daily report"
      },
      "founderFit": {
        "score": 6,
        "idealFor": "A solo or AI-assisted founder with direct access to Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed..",
        "advantages": [
          "Can talk to the buyer before writing much code.",
          "Can ship a narrow first-win demo quickly.",
          "Can use local-first research artifacts to keep validation moving without a large team."
        ],
        "gaps": [
          "Needs real buyer access, not only desk research.",
          "Needs proof of budget or repeated urgency.",
          "Needs a crisp wedge before broad product work starts."
        ],
        "avoidIf": [
          "You cannot reach the buyer directly.",
          "The idea only sounds interesting but does not save time, money, risk, or reputation.",
          "You want to build the full platform before validating the first workflow."
        ],
        "nextMove": "Run the lead magnet and first-win demo tests before promoting the broad version."
      },
      "roast": {
        "verdict": "Promising enough to test, not strong enough to build broadly.",
        "blindSpots": [
          "Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.",
          "A broad AI assistant can flatten differentiation unless the wedge is painfully specific.",
          "The first release can become a generic dashboard if the job is not named tightly."
        ],
        "hardQuestions": [
          "Who wakes up already trying to solve this?",
          "What do they stop paying for or stop doing when this works?",
          "What proof would make a skeptical buyer trust it in one screen?",
          "What is the smallest paid version of this idea?"
        ],
        "deRiskingMoves": [
          "Sell a manual pilot before building automation.",
          "Record five exact phrases buyers use to describe the pain.",
          "Cut any feature that does not support the first measurable win."
        ]
      },
      "buildActions": [
        "Delete any report section that feels generic before building.",
        "Run the lead magnet and first-win demo tests.",
        "Promote to deeper implementation only once the wedge survives interviews or paid-pilot outreach."
      ],
      "handoffPrompts": {
        "buildPrompt": "Build a narrow MVP for \"GLP-1 pharmacy index\" for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.. Preserve the evidence, build only the first-win workflow, include source links, and treat Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed. as the first acceptance gate.",
        "reviewPrompt": "Review the \"GLP-1 pharmacy index\" MVP for over-breadth, unsupported claims, weak buyer proof, privacy risk, and missing validation instrumentation. Do not approve expansion until the kill criteria and success metrics are measurable."
      },
      "killCriteria": [
        "Fewer than five qualified buyers agree to discuss the workflow after targeted outreach.",
        "No buyer can name a current cost in time, money, risk, or reputation.",
        "The first demo does not produce a clear next step, paid pilot, or specific objection."
      ],
      "sourceDetails": [
        {
          "title": "GLP-1 No Longer on FDA's Drug Shortage List",
          "url": "https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list",
          "sourceType": "trade media",
          "summary": "Reports that injectable tirzepatide (Mounjaro/Zepbound) came off the FDA shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, marking the shift from a national shortage to residual, localized supply issues."
        },
        {
          "title": "Telehealth company Ro launches GLP-1 supply tracker to help patients navigate shortages",
          "url": "https://www.cnbc.com/2024/05/29/ro-launches-glp-1-supply-tracker-to-help-patients-navigate-shortages.html",
          "sourceType": "business media",
          "summary": "Describes Ro's free, open-access GLP-1 Supply Tracker that combines crowdsourced patient reports with the FDA shortage list and alerts users when a needed drug and dose is found within 100 miles, demonstrating real consumer demand for dose-level availability data."
        },
        {
          "title": "Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site",
          "url": "https://www.cnbc.com/2025/12/01/eli-lilly-prices-zepbound-weight-loss-drug-vials.html",
          "sourceType": "business media",
          "summary": "Details manufacturer cash-pay price cuts on LillyDirect for Zepbound vials and the broader self-pay GLP-1 pricing war with Novo Nordisk's NovoCare, evidencing the wide, channel-dependent price variation a price index would normalize."
        },
        {
          "title": "How Much of Employers' Annual Claims Do GLP-1 Drugs Account For?",
          "url": "https://www.shrm.org/topics-tools/news/benefits-compensation/glp1-drugs-employers-annual-claims-may-2025",
          "sourceType": "industry research",
          "summary": "SHRM analysis showing GLP-1 drugs now represent roughly 20% of total prescription drug costs and about 10.5% of total annual employer pharmacy claims in 2025, establishing the B2B buyer's cost pressure and willingness to pay for steering data."
        }
      ]
    }
  },
  "calendarIcs": "BEGIN:VCALENDAR\r\nVERSION:2.0\r\nPRODID:-//IdeaNavigator AI//Execution Plan//EN\r\nCALSCALE:GREGORIAN\r\nMETHOD:PUBLISH\r\nX-WR-CALNAME:IdeaNavigator: GLP-1 pharmacy index\r\nBEGIN:VEVENT\r\nUID:glp-1-pharmacy-index-1@ideanavigatorai.com\r\nDTSTAMP:20260710T080000Z\r\nDTSTART;VALUE=DATE:20260710\r\nDTEND;VALUE=DATE:20260711\r\nSUMMARY:Frame the wedge\r\nDESCRIPTION:Write the one-sentence promise and test it in the strongest cha\r\n nnel.\\n\\nProof: Within 60 days\\, build a single-metro crowdsourced stock +\r\n  cash-price tracker for the four brand GLP-1s and run a paid landing-page \r\n test to two buyer segments: a 'find my dose cheapest near me' consumer pag\r\n e\\, and a B2B page pitching the normalized availability/price API to teleh\r\n ealth and employer-benefits teams. Validate if at least 200 consumer stock\r\n  reports are submitted in one metro and at least two B2B prospects sign a \r\n paid pilot or LOI for the feed.\\nOpen builder: https://ideanavigatorai.com\r\n /idea-builder/?idea=glp-1-pharmacy-index\\nReport: https://ideanavigatorai.\r\n com/ideas/glp-1-pharmacy-index/\\nNote: Plan dates are anchored to the repo\r\n rt publish date (2026-07-10)\\; shift them to your real start date when imp\r\n orting.\r\nURL:https://ideanavigatorai.com/idea-builder/?idea=glp-1-pharmacy-index\r\nBEGIN:VALARM\r\nACTION:DISPLAY\r\nDESCRIPTION:Validation test due soon: Within 60 days\\, build a single-metro\r\n  crowdsourced stock + cash-price tracker for the four brand GLP-1s and run\r\n  a paid landing-page test to two buyer segments: a 'find my dose cheapest \r\n near me' consumer page\\, and a B2B page pitching the normalized availabili\r\n ty/price API to telehealth and employer-benefits teams. Validate if at lea\r\n st 200 consumer stock reports are submitted in one metro and at least two \r\n B2B prospects sign a paid pilot or LOI for the feed.\r\nTRIGGER:-P7D\r\nEND:VALARM\r\nEND:VEVENT\r\nBEGIN:VEVENT\r\nUID:glp-1-pharmacy-index-2@ideanavigatorai.com\r\nDTSTAMP:20260710T080000Z\r\nDTSTART;VALUE=DATE:20260713\r\nDTEND;VALUE=DATE:20260714\r\nSUMMARY:Interview 10 people who match the buyer persona.\r\nDESCRIPTION:Create the lead magnet and use it to recruit interviews.\\n\\nPro\r\n of: Problem resonance: 5+ calls or 10+ detailed replies.\\nOpen builder: ht\r\n tps://ideanavigatorai.com/idea-builder/?idea=glp-1-pharmacy-index\\nReport:\r\n  https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/\\nNote: Plan dates\r\n  are anchored to the report publish date (2026-07-10)\\; shift them to your\r\n  real start date when importing.\r\nURL:https://ideanavigatorai.com/idea-builder/?idea=glp-1-pharmacy-index\r\nEND:VEVENT\r\nBEGIN:VEVENT\r\nUID:glp-1-pharmacy-index-3@ideanavigatorai.com\r\nDTSTAMP:20260710T080000Z\r\nDTSTART;VALUE=DATE:20260717\r\nDTEND;VALUE=DATE:20260718\r\nSUMMARY:Ship a clickable demo or concierge workflow that produces the first\r\n  useful artifact.\r\nDESCRIPTION:Build the smallest demo that proves the first win.\\n\\nProof: Ac\r\n tivation: 25% of demo visitors complete the first-win path.\\nOpen builder:\r\n  https://ideanavigatorai.com/idea-builder/?idea=glp-1-pharmacy-index\\nRepo\r\n rt: https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/\\nNote: Plan da\r\n tes are anchored to the report publish date (2026-07-10)\\; shift them to y\r\n our real start date when importing.\r\nURL:https://ideanavigatorai.com/idea-builder/?idea=glp-1-pharmacy-index\r\nEND:VEVENT\r\nBEGIN:VEVENT\r\nUID:glp-1-pharmacy-index-4@ideanavigatorai.com\r\nDTSTAMP:20260710T080000Z\r\nDTSTART;VALUE=DATE:20260724\r\nDTEND;VALUE=DATE:20260725\r\nSUMMARY:Run one paid pilot or collect explicit pricing objections before au\r\n tomating the rest.\r\nDESCRIPTION:Delete any report section that feels generic before building.\\n\r\n \\nProof: Commercial pull: 3 paid pilots\\, LOIs\\, or concrete procurement n\r\n ext steps.\\nOpen builder: https://ideanavigatorai.com/idea-builder/?idea=g\r\n lp-1-pharmacy-index\\nReport: https://ideanavigatorai.com/ideas/glp-1-pharm\r\n acy-index/\\nNote: Plan dates are anchored to the report publish date (2026\r\n -07-10)\\; shift them to your real start date when importing.\r\nURL:https://ideanavigatorai.com/idea-builder/?idea=glp-1-pharmacy-index\r\nEND:VEVENT\r\nBEGIN:VEVENT\r\nUID:glp-1-pharmacy-index-5@ideanavigatorai.com\r\nDTSTAMP:20260710T080000Z\r\nDTSTART;VALUE=DATE:20260731\r\nDTEND;VALUE=DATE:20260801\r\nSUMMARY:Promote to a deeper build plan only after the wedge survives valida\r\n tion.\r\nDESCRIPTION:Run the lead magnet and first-win demo tests.\\n\\nProof: Fewer t\r\n han five qualified buyers agree to discuss the workflow after targeted out\r\n reach.\\nOpen builder: https://ideanavigatorai.com/idea-builder/?idea=glp-1\r\n -pharmacy-index\\nReport: https://ideanavigatorai.com/ideas/glp-1-pharmacy-\r\n index/\\nNote: Plan dates are anchored to the report publish date (2026-07-\r\n 10)\\; shift them to your real start date when importing.\r\nURL:https://ideanavigatorai.com/idea-builder/?idea=glp-1-pharmacy-index\r\nEND:VEVENT\r\nBEGIN:VEVENT\r\nUID:glp-1-pharmacy-index-6@ideanavigatorai.com\r\nDTSTAMP:20260710T080000Z\r\nDTSTART;VALUE=DATE:20260809\r\nDTEND;VALUE=DATE:20260810\r\nSUMMARY:Execution checkpoint 6\r\nDESCRIPTION:Promote to deeper implementation only once the wedge survives i\r\n nterviews or paid-pilot outreach.\\n\\nProof: Promote to a deeper build plan\r\n  only after the wedge survives validation.\\nOpen builder: https://ideanavi\r\n gatorai.com/idea-builder/?idea=glp-1-pharmacy-index\\nReport: https://idean\r\n avigatorai.com/ideas/glp-1-pharmacy-index/\\nNote: Plan dates are anchored \r\n to the report publish date (2026-07-10)\\; shift them to your real start da\r\n te when importing.\r\nURL:https://ideanavigatorai.com/idea-builder/?idea=glp-1-pharmacy-index\r\nEND:VEVENT\r\nEND:VCALENDAR\r\n",
  "exports": {
    "bundleUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.bundle.json",
    "jsonUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.json",
    "markdownUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.md",
    "calendarUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index.ics",
    "backlogUrl": "https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/backlog.json"
  }
}